ATLANTA, July 25 /PRNewswire-FirstCall/ -- Inhibitex, Inc. announced today it will host a conference call on Thursday, August 3, 2006 at 8:30 a.m. EDT to review its second quarter 2006 financial results and provide an update on corporate developments. The Company will issue a press release on the same day, prior to the conference call.
To access the conference call, please dial 800-659-2032 (domestic) or 617- 614-2712 (international) and reference the access code 88004539. A replay of the call will be available from 10:30 a.m. EDT on August 3, until September 3, 2006 at midnight. To access the replay, please dial 888-286-8010 (domestic) or 617-801-6888 (international) and reference the access code 48980699. A live audio webcast of the call and the archived webcast will be available in the Investors section of the Inhibitex website http://www.inhibitex.com.
About Inhibitex
Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a biopharmaceutical company focused on the discovery, development and commercialization of antibody-based products for the prevention and treatment of serious, life-threatening infections. All of the company's drug development programs are based on its proprietary MSCRAMM(R) protein platform. MSCRAMM proteins are located on the surface of pathogenic organisms, and are responsible for the initiation and spread of infections. The company's pipeline consists of Aurexis(R) for the treatment of S. aureus bloodstream infections and five preclinical programs that include a collaboration and joint development agreement with Dyax to develop fully human monoclonal antibodies against MSCRAMM proteins on enterococci and a partnership with Wyeth to develop staphylococcal vaccines. For additional information about the company, please visit www.inhibitex.com.
Inhibitex(R), MSCRAMM(R), Veronate(R) and Aurexis(R) are registered trademarks of Inhibitex, Inc.
CONTACTS: Inhibitex, Inc. Russell H. Plumb Chief Financial Officer (678) 746-1136 rplumb@inhibitex.com Lilian Stern (Investors) Stern Investor Relations, Inc. (212) 362-1200 lilian@sternir.com
Inhibitex, Inc.CONTACT: Russell H. Plumb, Chief Financial Officer, of Inhibitex, Inc.,+1-678-746-1136, or rplumb@inhibitex.com; or Lilian Stern (Investors) ofStern Investor Relations, Inc., +1-212-362-1200, or lilian@sternir.com
Web site: http://www.inhibitex.com/
